etidronate and Bone Cancer studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

Excerpt	Relevance	Reference
"Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C)."	9.11	[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"The aim of this study was to evaluate the efficacy of 186Re-1,1-hydroxyethylidene diphosphonate (etidronate) in breast cancer patients with painful bone metastases."	9.09	186Re-etidronate in breast cancer patients with metastatic bone pain. ( Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999)
"To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief."	9.09	Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."	9.09	[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."	9.09	[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."	9.08	[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."	8.79	Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
" Clinical studies indicated a benefit in survival and tumor relapse in subpopulations of breast cancer patients receiving zoledronic acid, thus stimulating the debate about its anti-tumor activity."	7.80	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."	7.75	Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"The aims of the present study were to determine whether patients with painful bone metastases from primary cancer sites showed a higher level of a bone resorption marker than those with no evidence of skeletal-related events, and to clarify the efficacy of oral administration of etidronate for pain due to bone metastases and bone resorption."	7.71	Transient relief of metastatic cancer bone pain by oral administration of etidronate. ( Ichimura, S; Iwamoto, J; Takeda, T, 2002)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."	7.70	Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
"A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia."	7.69	Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994)
"Administration of 400 mg of etidronate in cases of refractory metastatic bone pain."	7.69	Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. ( Gloth, FM, 1995)
"Twenty-one patients with multiple myeloma were examined in close time relation with skeletal X-ray survey and bone scanning using technetium diphosphonate."	7.66	Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. ( Lindström, E; Lindström, FD, 1980)
"Twelve patients with metastatic breast cancer were studied."	6.68	Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
"A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38."	5.31	Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000)
"Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C)."	5.11	[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain."	5.10	Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. ( Kotzerke, J; Kropp, J; Liepe, K; Runge, R, 2003)
"The aim of this study was to evaluate the efficacy of 186Re-1,1-hydroxyethylidene diphosphonate (etidronate) in breast cancer patients with painful bone metastases."	5.09	186Re-etidronate in breast cancer patients with metastatic bone pain. ( Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."	5.09	[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief."	5.09	Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."	5.09	[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"The aim of this study was to evaluate the efficacy of rhenium-186 hydroxyethyledine diphosphonate (Re-186 HEDP) for pain relief in patients with disseminated bone metastases primarily from prostate or breast cancer."	5.08	Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. ( Biersack, HJ; Dierke-Dzierzon, C; Müller, SC; Palmedo, H; Schoeneich, G, 1997)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."	5.08	[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."	4.79	Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
" Clinical studies indicated a benefit in survival and tumor relapse in subpopulations of breast cancer patients receiving zoledronic acid, thus stimulating the debate about its anti-tumor activity."	3.80	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."	3.75	Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"The aims of the present study were to determine whether patients with painful bone metastases from primary cancer sites showed a higher level of a bone resorption marker than those with no evidence of skeletal-related events, and to clarify the efficacy of oral administration of etidronate for pain due to bone metastases and bone resorption."	3.71	Transient relief of metastatic cancer bone pain by oral administration of etidronate. ( Ichimura, S; Iwamoto, J; Takeda, T, 2002)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."	3.70	Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
" When used orally, it can, as can pamidronate, reduce the skeletal complications of breast cancer such as hypercalcemia, bone fractures and bone pain."	3.69	Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995)
"Administration of 400 mg of etidronate in cases of refractory metastatic bone pain."	3.69	Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. ( Gloth, FM, 1995)
"A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia."	3.69	Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994)
"To define the nature, incidence and consequence of a possible interaction between etidronate (for the treatment of hypercalcemia) and methylene diphosphonate labelled with technetium-99m (99mTc-MDP) (for bone scanning)."	3.69	Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. ( Line, BR; Malfetano, J; Murphy, KJ, 1997)
"Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease."	3.68	Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. ( Eary, JF; Hommeyer, SH; Varney, DM, 1992)
"Twenty-one patients with multiple myeloma were examined in close time relation with skeletal X-ray survey and bone scanning using technetium diphosphonate."	3.66	Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. ( Lindström, E; Lindström, FD, 1980)
"Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia."	3.66	Parenteral diphosphonates for treating malignant hypercalcemia. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1981)
"Prostate or breast cancer patients with painful bone metastases receiving (188)Re-HEDP as a routine clinical procedure were eligible for evaluation."	2.82	Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. ( Bloemendal, HJ; de Klerk, JM; Hendrikse, NH; Kooistra, A; Lange, R; Overbeek, F; Pasker-de Jong, PC; Rodenburg, CJ; Ter Heine, R; van den Berk, AM, 2016)
"A dose escalation schedule was designed consisting of four dose levels with a standard dosage of docetaxel (75 mg/m(2) 3-weekly)."	2.76	A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). ( Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH, 2011)
"Patients with hormone-refractory prostate cancer were treated with capecitabine for 14 days (oral twice daily in a dose escalation regimen with steps of 1/3 of 2,500 mg/m(2) per day in cohorts of three to six patients, depending on toxicity)."	2.74	(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009)
"In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr)."	2.73	A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. ( Kotzerke, J; Liepe, K, 2007)
" The dosage of opiates was decreased in 77% of the patients and could be discontinued in 4 of them."	2.71	Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. ( Anagnostopoulou, US; Datseris, EI; Leondi, AH; Leontopoulou, SA; Papadaki, EK; Rapti, AS; Souvatzoglou, MA; Zerva, CJ, 2004)
"Thirteen prostate cancer patients with skeletal involvement were treated with 2,700-3,459 MBq (mean dose, 3,120 MBq) (188)Re-HEDP."	2.71	Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. ( Franke, WG; Hliscs, R; Knapp, FF; Kropp, J; Liepe, K; Runge, R, 2003)
"It is concluded that in prostate cancer patients, the maximum tolerated dose of 188Re-HEDP is 3."	2.69	Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. ( Bender, H; Biersack, HJ; Grünwald, F; Guhlke, S; Knapp, FF; Palmedo, H; Risse, J; Sartor, J; Schoeneich, G, 2000)
" Of the six patients treated at the highest dosage schedules (three at 1510 MBq/m2 and three at 1665 MBq/m2), three showed a posttherapy decline in prostate-specific antigen of 50% or more."	2.69	Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. ( Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD, 1999)
" No major adverse effects were observed."	2.69	Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. ( Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000)
"Twelve patients with metastatic breast cancer were studied."	2.68	Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
"Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1."	2.66	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020)
"Many patients with cancer develop symptomatic skeletal metastases at an advanced stage of their disease."	2.44	Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. ( de Klerk, JM; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2007)
" The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used."	2.43	Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006)
"Pamidronate has been found to be effective in reducing skeletal morbidity associated with bone metastases in both multiple myeloma and breast carcinoma patients when given intravenously, but is ineffective orally in multiple myeloma patients."	2.41	Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
"Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity."	2.40	Bisphosphonates and breast carcinoma. ( Lipton, A, 1997)
"Haematologic malignancies and solid tumors are often complicated by the bone tissue destruction."	2.39	[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. ( Kiełbiński, M, 1994)
" This study shows the importance of patient stratification to establish absorbed dose-response correlations and indicates the potential to individualise treatment of bone metastases with radiopharmaceuticals according to patient-specific imaging and dosimetry."	1.46	Phase I/II trials of ( Chittenden, SJ; Dearnaley, DP; Denis-Bacelar, AM; Divoli, A; Du, Y; Flux, GD; Johnson, B; McCready, VR; O'Sullivan, JM, 2017)
" Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents."	1.39	Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. ( Gouliamos, A; Limouris, GS; Sideras, PA; Stavraka, A, 2013)
"Breast or prostate cancer patients were treated with zoledronate."	1.39	Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013)
"The indication for BP was prevention or treatment of osteoporosis in 11 cases and breast with bone metastases in one case."	1.36	[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010)
"Here, in a new approach for bone metastasis prevention, we employed poly-l-lysine covalently grafted with beta-cyclodextrin as a polycationic vector (PLL-CD) for the antitumor bisphosphonate drug risedronate (RIS)."	1.35	Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. ( Atmani, H; Benkirane-Jessel, N; Clézardin, P; Cortial, D; Daubiné, F; Haïkel, Y; Ladam, G; Voegel, JC, 2009)
"Osteosarcoma is a highly malignant bone tumor and is the most commonly encountered malignant bone tumor in children and adolescents."	1.35	Risedronate inhibits human osteosarcoma cell invasion. ( Jung, ST; Kim, YK; Xin, ZF, 2009)
"33 patients (30 prostate carcinoma, 3 breast carcinoma) were treated with 150 MBq 89SrCl2 (9 patients), 1295 MBq 186Re-HEDP (12 patients) or 37 MBq/kg 153Sm-EDTMP (12 patients)."	1.35	Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP. ( de Klerk, JM; Hoekstra, A; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009)
"Here, we used a mouse model of human breast cancer bone metastasis to examine the effects of risedronate and NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, on osteolysis and tumor growth."	1.35	Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. ( Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ, 2008)
"Risedronate decreased bone cancer-related bone destruction and pain-related behavior and decreased the spinal expression of glial fibrillary acidic protein, whereas NE-10790 had no effect on these parameters."	1.35	Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. ( Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW, 2009)
"Patients with skeletal metastases from hormone-refractory prostate cancer have shown variable responses to high-activity therapy with (186)Re-HEDP and peripheral stem cell support."	1.33	The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer. ( Binnie, D; Dearnaley, D; Divoli, A; Flux, G; McCready, VR, 2005)
"A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38."	1.31	Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000)
" However, by this new scintigraphic quantification method, bone uptake and soft-tissue retention can be calculated separately, thus providing more detailed kinetic data and potentially improving the dosimetry of these radiopharmaceuticals in, for example, assessment of radiation dosage to bone and bone marrow."	1.31	Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. ( Brenner, W; Henze, E; Kampen, AM; Kampen, WU, 2001)
"Although the function of normal bone marrow is affected by metastases in patients with metastatic bone disease, the MIRD model can be used to relate toxicity to the bone marrow absorbed dose after a therapeutic dosage of 186Re-HEDP."	1.29	Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. ( Blijham, GH; de Klerk, JM; Hoekstra, A; Rutgers, DH; van Dieren, EB; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
"Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia."	1.29	Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995)
"We report on two prostatic cancer patients with metastatic bone cancer."	1.29	Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. ( Blijham, GH; de Klerk, JM; Krouwer, HG; van Die, J; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996)
" Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40."	1.28	Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. ( de Klerk, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1992)
"All three are useful for the treatment of hypercalcemia, but pamidronate seems to be the most effective."	1.28	Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991)
"sarcoma 180 was in fact related to alterations of osseous tissues by EHDP."	1.27	Effects of disodium etidronate in murine tumor models. ( Coccioli, G; Corti, F; Donelli, MG; Filippeschi, S; Garattini, S; Guaitani, A; Italia, C; Mantovani, A; Marmonti, L; Polentarutti, N, 1984)
"Hospital records of 27 children with osteogenic sarcoma were reviewed in an effort to define the usefulness of skeletal scintigraphy in the initial evaluation and follow-up of their disease."	1.27	The role of bone scintigraphy in osteogenic sarcoma. ( duCret, R; Rees, CR; Siddiqui, AR, 1986)
"Etidronate was also found to prevent bone metastasis in syngeneic rat mammary carcinoma."	1.27	Effect of etidronate disodium on the interactions between malignancy and bone. ( Garattini, S; Guaitani, A; Mantovani, A, 1987)
"A 77-year-old man with prostate cancer was serially evaluated for bone metastases using Tc-99m methylene disphosphonate (Tc-99m MDP) both on and off treatment with etidronate disodium (EHDP)."	1.27	False-negative bone imaging due to etidronate disodium therapy. ( Collier, BD; Ewey, D; Hellman, RS; Isitman, AT; Krasnow, AZ, 1988)
"This osteolysis was evaluated by measuring the increased area of bone resorption by its reduced opacity to X-ray, and histology."	1.27	Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice. ( Harada, M; Kanoh, S; Koiso, K; Nemoto, R, 1988)

Research

Studies (203)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	56 (27.59)	18.7374
1990's	55 (27.09)	18.2507
2000's	62 (30.54)	29.6817
2010's	27 (13.30)	24.3611
2020's	3 (1.48)	2.80

Authors	Studies
Pourhabib, Z	1
Ranjbar, H	1
Bahrami Samani, A	1
Alshehri, AHD	1
Osman, SOS	1
Prise, KM	1
Campfield, C	1
Turner, PG	1
Jain, SFP	1
O'Sullivan, JM	9
Cole, AJ	1
Jakob, T	1
Tesfamariam, YM	1
Macherey, S	1
Kuhr, K	1
Adams, A	1
Monsef, I	1
Heidenreich, A	1
Skoetz, N	1
van Dodewaard-de Jong, JM	2
de Klerk, JMH	1
Bloemendal, HJ	6
Oprea-Lager, DE	2
Hoekstra, OS	2
van den Berg, HP	1
Los, M	1
Beeker, A	1
Jonker, MA	1
Verheul, HMW	1
van den Eertwegh, AJM	1
Sharma, R	1
Kumar, C	1
Mallia, MB	2
Kameswaran, M	2
Sarma, HD	2
Banerjee, S	3
Dash, A	1
Deilami-Nezhad, L	1
Moghaddam-Banaem, L	1
Sadeghi, M	1
Denis-Bacelar, AM	2
Chittenden, SJ	3
McCready, VR	6
Divoli, A	4
Dearnaley, DP	6
Johnson, B	3
Flux, GD	4
Nomura, T	1
Shibahara, T	1
Uchiyama, T	1
Yamamoto, N	1
Shibui, T	1
Yakushiji, T	1
Watanabe, A	1
Muramatsu, K	1
Ogane, S	1
Murayama, M	1
Sekine, R	1
Nakata, E	1
Fujimoto, Y	1
Pirayesh, E	1
Amoui, M	1
Mirzaee, HR	1
Tabei, F	1
Rakhsha, A	1
Kalantari, BA	1
Shafiei, B	1
Assadi, M	1
Asli, IN	1
ter Heine, R	3
Lange, R	3
Breukels, OB	1
Rummenie, RG	1
Wakker, AM	1
de Graaf, H	1
Beekman, FJ	1
van der Westerlaken, MM	1
Malingré, MM	1
Wielders, JP	1
van den Berg, L	1
Hendrikse, NH	3
de Klerk, JM	18
Ebert, R	1
Meissner-Weigl, J	1
Zeck, S	1
Määttä, J	1
Auriola, S	1
Coimbra de Sousa, S	1
Mentrup, B	1
Graser, S	1
Rachner, TD	1
Hofbauer, LC	1
Jakob, F	1
Bagheri, R	1
Afarideh, H	1
Maragheh, MG	1
Shirmardi, SP	1
Samani, AB	1
Jong, JM	1
Hooft, L	1
Verheul, HM	1
van den Eertwegh, AJ	1
Shinto, AS	1
Kamaleshwaran, KK	1
Kalarikal, R	1
Aswathy, KK	1
Overbeek, F	1
Pasker-de Jong, PC	1
van den Berk, AM	1
Rodenburg, CJ	1
Kooistra, A	1
Du, Y	1
van Wieringen, WN	1
Tromp, AM	1
Paap, M	1
Geldof, AA	1
Margiotta, N	1
Capitelli, F	1
Ostuni, R	1
Natile, G	1
Lawson, MA	1
Coulton, L	1
Ebetino, FH	4
Vanderkerken, K	1
Croucher, PI	2
Fournier, PG	2
Daubiné, F	2
Lundy, MW	1
Rogers, MJ	1
Clézardin, P	3
Lam, MG	4
Hoekstra, A	2
van Rijk, PP	14
Zonnenberg, BA	12
Bosma, TB	1
Hald, A	1
Hansen, RR	1
Thomsen, MW	1
Ding, M	1
Gallagher, O	1
Kassem, M	1
Heegaard, AM	1
Liepe, K	8
Geidel, HH	1
Bergmann, R	1
Haase, M	1
Runge, R	6
Kotzerke, J	4
Xin, ZF	1
Kim, YK	1
Jung, ST	1
Cortial, D	1
Ladam, G	1
Atmani, H	1
Haïkel, Y	1
Voegel, JC	1
Benkirane-Jessel, N	1
Zafeirakis, A	2
Zissimopoulos, A	2
Baziotis, N	2
Limouris, GS	3
Migliorati, CA	1
Mattos, K	1
Palazzolo, MJ	1
Stresing, V	1
Barrier, A	1
Lescaille, G	1
Rigolet, A	1
Descroix, V	1
Goudot, P	1
Ruhin, B	1
Cheng, A	1
Chen, S	1
Zhang, Y	1
Yin, D	1
Dong, M	1
Chiacchio, S	1
Mazzarri, S	2
Lorenzoni, A	1
Nyakale, N	1
Boni, G	1
Borsò, E	1
Alsharif, A	1
Grosso, M	1
Manca, G	1
Greco, C	1
Volterrani, D	1
Mariani, G	2
van Bezooijen, BP	1
de Haas, MJ	1
Wilson, RH	1
Biersack, HJ	8
Palmedo, H	8
Andris, A	1
Rogenhofer, S	1
Knapp, FF	6
Guhlke, S	3
Ezziddin, S	2
Bucerius, J	1
von Mallek, D	1
Berglund, J	1
Ozkal-Baydin, P	1
Gümüş-Akay, G	1
Varol, N	1
Rüstemoğlu, A	1
Köroğlu, R	1
Yüksel, S	1
Küçük, O	1
Aras, G	2
Ibiş, E	2
Sunguroğlu, A	1
Meulenbeld, HJ	1
van Werkhoven, ED	1
Coenen, JL	1
Creemers, GJ	1
Loosveld, OJ	1
de Jong, PC	1
Ten Tije, AJ	1
Fosså, SD	1
Polee, M	1
Gerritsen, W	1
Dalesio, O	1
de Wit, R	1
Orsini, F	1
Guidoccio, F	1
Sideras, PA	1
Stavraka, A	1
Gouliamos, A	1
Iwamoto, J	1
Takeda, T	1
Ichimura, S	1
Han, SH	6
Tan, S	2
van het Schip, AD	9
Derksen, BH	1
van Dijk, A	9
Kruitwagen, CL	1
Blijham, GH	8
Silberstein, EB	6
Taylor, AT	1
Buffa, FM	3
Guy, MJ	1
Hliscs, R	4
Kropp, J	5
Franke, WG	4
Manka-Waluch, A	1
Albers, P	1
Schmidt-Wolf, IG	1
Reinhardt, M	1
Joe, A	1
Roedel, R	1
Fimmers, R	1
Scheffler, J	1
Derejko, M	1
Bandurski, T	1
Romanowicz, G	1
Zhang, H	2
Tian, M	2
Li, S	2
Liu, J	2
Tanada, S	1
Endo, K	1
Leondi, AH	1
Souvatzoglou, MA	1
Rapti, AS	1
Leontopoulou, SA	1
Papadaki, EK	1
Datseris, EI	1
Anagnostopoulou, US	1
Zerva, CJ	1
Saba, N	1
Khuri, F	1
Binnie, D	1
Dearnaley, D	1
Flux, G	3
Liang, JG	1
Jiang, NY	1
DU, JQ	1
Lu, XP	1
Liu, XG	1
Chen, SX	1
Norman, AR	2
Coffey, J	1
Cook, G	2
Treleaven, J	2
Horwich, A	2
Huddart, RA	2
Parker, CC	1
Maini, CL	4
Sciuto, R	4
Romano, L	1
Bergomi, S	2
van der Poel, HG	1
Antonini, N	1
Hoefnagel, CA	1
Horenblas, S	1
Valdes Olmos, RA	1
Minutoli, F	1
Herberg, A	1
Spadaro, P	1
Restifo Pecorella, G	1
Baldari, S	2
Aricò, D	1
Altavilla, G	1
Syed, R	1
Bomanji, J	1
Nagabhushan, N	1
Kayani, I	1
Groves, A	1
Waddington, W	1
Cassoni, A	1
Ell, PJ	2
Bobba, RS	1
Beattie, K	1
Parkinson, B	1
Kumbhare, D	1
Adachi, JD	1
Strigari, L	1
D'Andrea, M	1
Pasqualoni, R	3
Benassi, M	1
Bloch, G	1
Chittenden, S	2
Malaroda, A	1
Malden, NJ	1
Pai, AY	1
El-Mabhouh, AA	1
Mercer, JR	1
Udvardy, E	1
Redl, P	1
Márton, I	1
Koutsikos, J	2
Leondi, A	2
Schnur, W	3
Fogelman, I	3
Delmas, PD	1
Meunier, PJ	1
Nakano, S	2
Hasegawa, Y	2
Kajita, A	3
Nakamura, S	1
Horai, T	1
Ikegami, H	1
Matuda, M	1
Okamoto, N	1
Nabeshima, H	1
Doi, O	1
Komatubara, Y	1
Ishigami, S	2
Rondier, J	1
Huchet, B	1
Cayla, J	1
Kumano, M	2
Tamura, K	1
Hamada, T	1
Ishida, O	1
Ushio, K	1
Okuno, T	1
Guaitani, A	3
Polentarutti, N	1
Filippeschi, S	1
Marmonti, L	1
Corti, F	1
Italia, C	1
Coccioli, G	2
Donelli, MG	1
Mantovani, A	2
Garattini, S	3
Weininger, J	1
Ketring, AR	2
Deutsch, EA	4
Simon, MA	1
Kirchner, PT	1
Lindström, E	1
Lindström, FD	1
Jung, A	1
van Ouwenaller, C	1
Chantraine, A	1
Courvoisier, B	1
Hikita, C	1
Yamagishi, Y	1
Okuyama, A	1
Wallach, S	1
Quirijnen, JM	4
Robinson, RG	1
Preston, DF	1
Schiefelbein, M	1
Baxter, KG	1
Sasaki, A	2
Boyce, BF	2
Story, B	1
Wright, KR	2
Chapman, M	1
Boyce, R	1
Mundy, GR	2
Yoneda, T	2
McEwan, AJ	2
Lewington, VJ	1
Samaratunga, RC	3
Thomas, SR	7
Hinnefeld, JD	1
Von Kuster, LC	1
Hyams, DM	1
Moulton, JS	5
Sperling, MI	1
Maxon, HR	8
Kiełbiński, M	1
Stokkel, MP	1
Hall, DG	1
Stoica, G	1
van Dieren, EB	1
Rutgers, DH	1
Hughes, DE	1
Uy, HL	1
Roodman, GD	1
Reginster, JY	1
Bender, H	3
Schomburg, A	1
Grünwald, F	3
Schöneich, G	1
Zamorra, P	1
Reichmann, K	1
Dierke-Dzierzon, C	4
Mallmann, P	1
Krouwer, HG	1
van Die, J	1
Gloth, FM	1
ten Kroode, HF	1
Paterson, AH	1
Kanis, JA	2
Powles, TJ	1
McCloskey, E	1
Hanson, J	1
Ashley, S	1
Atkins, HL	1
Srivastava, SC	1
Body, JJ	2
Coleman, RE	3
Piccart, M	1
Lin, WY	2
Lin, CP	1
Yeh, SJ	1
Hsieh, BT	2
Tsai, ZT	1
Ting, G	2
Yen, TC	1
Wang, SJ	2
Stabin, MG	1
Murphy, KJ	1
Line, BR	1
Malfetano, J	1
van Aswegen, A	1
Roodt, A	1
Marais, J	1
Botha, JM	1
Naudé, H	1
Lötter, MG	1
Goedhals, L	1
Doman, MJ	1
Otto, AC	1
Lipton, A	3
Adami, S	1
Schoeneich, G	2
Müller, SC	1
Holle, LH	1
Humke, U	1
Trampert, L	1
Ziegler, M	1
Kirsch, CM	1
Oberhausen, E	1
Hauswirth, AE	1
Krebs, D	3
Schroder, LE	5
Washburn, LC	1
Biniakiewicz, D	1
Cummings, D	1
Ehrhardt, GJ	2
Morris, V	1
Goa, KL	1
Balfour, JA	1
Lerch, H	1
Wagner, U	1
Köhler, S	1
Zonneberg, BA	1
Graham, MC	1
Scher, HI	4
Liu, GB	1
Yeh, SD	1
Curley, T	2
Daghighian, F	1
Goldsmith, SJ	1
Larson, SM	1
Carl, UM	1
Risse, J	2
De Winter, F	1
Brans, B	1
Van De Wiele, C	1
Dierckx, RA	1
Major, PP	1
Berenson, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695]	Phase 2	0 participants	Interventional	1999-03-31	Terminated
Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558]	Phase 2	44 participants	Interventional	2001-12-31	Completed
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001]	Phase 3	645 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650]	Phase 2	111 participants (Actual)	Interventional	2005-01-31	Completed
Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232]	Phase 3	227 participants (Actual)	Interventional	1997-11-24	Completed
A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646]	Phase 3	227 participants (Actual)	Interventional	2008-05-31	Completed
A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918]	Phase 2	300 participants (Anticipated)	Interventional	2005-02-28	Completed
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620]	Phase 3	1,904 participants (Actual)	Interventional	2006-04-01	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060]	Phase 3	63 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to Terminated due to low accrual)
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476]	Phase 2/Phase 3	11,992 participants (Actual)	Interventional	2005-07-08	Active, not recruiting
Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study[NCT03458559]	Phase 3	402 participants (Anticipated)	Interventional	2018-05-16	Active, not recruiting
Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203]	Phase 2	120 participants (Actual)	Interventional	2002-10-31	Completed
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420]	Phase 1	4 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Progression-free Survival

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	37.9
Placebo + Androgen Deprivation Therapy	36.0

"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years

Time to First Skeletal Related Event

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	10.6
Placebo + Androgen Deprivation Therapy	9.2

Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	31.9
Placebo + Androgen Deprivation Therapy	28.8

Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25

Hypercalcemia

Intervention	Participants (Number)
Bisphosphonate IV Q4W	25
Denosumab 180 mg Q12W	32
Denosumab 180 mg Q4W	35

Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25

Percent Change of Serum CTX From Baseline to Week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	0
Denosumab 180 mg Q12W	0
Denosumab 180 mg Q4W	0

Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-40.68
Denosumab 180 mg Q12W	-76.74
Denosumab 180 mg Q4W	-68.39

Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Skeletal Related Events

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-32.91
Denosumab 180 mg Q12W	-69.09
Denosumab 180 mg Q4W	-41.68

Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Time to First Skeletal Related Event

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13

Intervention	Days (Median)
Bisphosphonate IV Q4W	65
Denosumab 180 mg Q12W	9
Denosumab 180 mg Q4W	10

Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	10
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	28

Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks

Time to the First On-Study SRE (Non-inferiority)

Intervention	Participants (Number)
Bisphosphonate IV Q4W	13
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	23

Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Time to the First On-Study SRE (Superiority)

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Time to the First-And-Subsequent On-Study SRE

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months

Numbers of SRE or Death Occurred Cumulatively

Intervention	Events (Number)
Zoledronic Acid	584
Denosumab	494

Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

Three- Year Survival Rate

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

Intervention	participants (Number)
Risedronate Arm	11
Placebo Arm	13

Intervention	percentage of participants (Number)
Risedronate Arm	50
Placebo Arm	29

Intervention	percentage of participants (Number)
Risedronate	72.5
Placebo	71.5

"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks

Bone Turnover Marker Changes-- Serum BAP

Intervention	nmol/mmol creatinine (Median)
	week 24	baseline
Placebo Arm	12.62	10.12
Risedronate Arm	6.91	8.83

Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Intervention	ng/mL (Median)
	24 week	baseline
Placebo Arm	13.16	19.50
Risedronate Arm	9.5	20.95

Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

Intervention	ug/L (Median)
	at 24 week	baseline
Placebo Arm	27.35	18.24
Risedronate Arm	11.88	20.08

"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week

Article	Year
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. European urology, 2016, Volume: 70, Issue:3 Topics: Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Etidronic Acid; Humans; Male; Organometallic Com	2016
Radionuclide therapy and integrated protocols for bone metastases. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:4 Topics: Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Etidronic Acid	2011
Application of rhenium-188 HEDP in bone metastases therapy. Nuclear medicine review. Central & Eastern Europe, 2003, Volume: 6, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Humans; Leukopenia; Organometallic Compounds; Pain; Palliative Care;	2003
186Re-HEDP for metastatic bone pain in breast cancer patients. European journal of nuclear medicine and molecular imaging, 2004, Volume: 31 Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum	2004
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology, 2005, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung;	2005
Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Organophosphorus Compounds; Pain;	2003
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug safety, 2006, Volume: 29, Issue:12 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac	2006
Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anti-cancer agents in medicinal chemistry, 2007, Volume: 7, Issue:4 Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Oncology; Models, Chemical	2007
[Osteonecrosis of the jaw developing during bisphosphonate treatment]. Magyar onkologia, 2008, Volume: 52, Issue:1 Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodelin	2008
Treatment of Paget's disease. Advances in internal medicine, 1982, Volume: 27 Topics: Adult; Aged; Alkaline Phosphatase; Animals; Bone and Bones; Bone Neoplasms; Calcitonin; Drug Therapy	1982
Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA, 1995, Aug-02, Volume: 274, Issue:5 Topics: Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Drugs, Investigational; Etidronic Acid; Fem	1995
Targeted radionuclide therapy for bone metastases. European journal of nuclear medicine, 1993, Volume: 20, Issue:1 Topics: Analgesics; Bone Neoplasms; Combined Modality Therapy; Etidronic Acid; Humans; Organometallic Compou	1993
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. Acta haematologica Polonica, 1994, Volume: 25, Issue:2 Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteo	1994
Radiolabeled bone-seeking radiopharmaceuticals. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1996, Volume: 40, Issue:3 Topics: Animals; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Pentetic Acid; Radioisotopes; Radioph	1996
Use of bisphosphonates in cancer patients. Cancer treatment reviews, 1996, Volume: 22, Issue:4 Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid	1996
Unsealed source therapy of painful bone metastases: an update. Seminars in nuclear medicine, 1997, Volume: 27, Issue:2 Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Male; Organometallic Compo	1997
Bisphosphonates and breast carcinoma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic	1997
Bisphosphonates in prostate carcinoma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C	1997
Risedronate. Drugs & aging, 1998, Volume: 13, Issue:1 Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor	1998
Aredia: the once-monthly infusion for the treatment of bone metastases. Current opinion in oncology, 1998, Volume: 10 Suppl 1 Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic;	1998
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm	2000
186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2001, Volume: 45, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pain, Intractable; P	2001
Bisphosphonates for the relief of pain secondary to bone metastases. The Cochrane database of systematic reviews, 2002, Issue:2 Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Eti	2002
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors. Advances in experimental medicine and biology, 1992, Volume: 324 Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances;	1992
Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Seminars in nuclear medicine, 1992, Volume: 22, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Pain; Palliative Care	1992
[Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism]. Der Internist, 1992, Volume: 33, Issue:6 Topics: Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Oste	1992
Bone metastases and tumor-induced hypercalcemia. Current opinion in oncology, 1992, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho	1992
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper	1990
Bone metastases and breast cancer. Cancer treatment reviews, 1985, Volume: 12, Issue:4 Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin	1985

Article	Year
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Fre	2017
Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. Journal of nuclear medicine technology, 2013, Volume: 41, Issue:3 Topics: Adult; Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compo	2013
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin. Nuclear medicine, 2016, Sep-26, Volume: 55, Issue:5 Topics: Aged; Bone Neoplasms; Breast Neoplasms; Cancer Pain; Comorbidity; Etidronic Acid; Female; Humans; Ma	2016
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:9 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Eti	2009
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer biotherapy & radiopharmaceuticals, 2011, Volume: 26, Issue:2 Topics: Blood Cell Count; Bone Neoplasms; Electrocardiography; Etidronic Acid; Female; Follow-Up Studies; Hu	2011
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:11 Topics: Aged; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Orchi	2011
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com	2012
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:9 Topics: Aged; Bone Neoplasms; Double-Blind Method; Etidronic Acid; Humans; Male; Organometallic Compounds; P	2002
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:8 Topics: Body Burden; Bone Marrow; Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Injections, I	2003
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:6 Topics: Aged; Aged, 80 and over; Body Burden; Bone Marrow; Bone Neoplasms; Etidronic Acid; Half-Life; Humans	2003
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15 Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Hu	2003
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4 Topics: Aged; Aged, 80 and over; Blood Cell Count; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged	2003
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:1 Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Etidronic Acid;	2005
Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2004, Volume: 48, Issue:3 Topics: Bone Neoplasms; Carcinoma; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organo	2004
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb	2005
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. European journal of nuclear medicine and molecular imaging, 2006, Volume: 33, Issue:9 Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Etidronic Acid; Humans;	2006
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2006, Volume: 50, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma	2006
186Re-HEDP in the treatment of patients with inoperable osteosarcoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Body Burden; Bone Neoplasms; Chemotherapy, Adjuvant; Child	2006
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nuclear medicine communications, 2007, Volume: 28, Issue:8 Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Et	2007
Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used. Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:1 Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Prostatic Neopl	2007
Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. European journal of nuclear medicine, 1994, Volume: 21, Issue:10 Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prost	1994
Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:2 Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Dose-Response Rela	1996
Dosage and response in radiopharmaceutical therapy of painful osseous metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum	1996
[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. Nuklearmedizin. Nuclear medicine, 1996, Volume: 35, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Met	1996
Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:9 Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Pain Measurement; Palliative Care; Prostatic Neoplasms	1996
Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. Scandinavian journal of urology and nephrology, 1997, Volume: 31, Issue:5 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa	1997
186Re-etidronate in breast cancer patients with metastatic bone pain. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:4 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Organometallic Compounds; Pain, In	1999
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:6 Topics: Androgens; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Kidney; Ma	1999
Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. American journal of clinical oncology, 2000, Volume: 23, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma	2000
Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. European journal of nuclear medicine, 2000, Volume: 27, Issue:2 Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Pain Measuremen	2000
[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. Orvosi hetilap, 2000, May-07, Volume: 141, Issue:19 Topics: Alkaline Phosphatase; Analgesics; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans;	2000
Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid	2000
Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle	2000
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. Nuklearmedizin. Nuclear medicine, 2000, Volume: 39, Issue:6 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged	2000
Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast cancer research and treatment, 2001, Volume: 66, Issue:2 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Etidronic Acid; Female; Humans	2001
Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2001, Volume: 45, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain, Intractable; Palliativ	2001
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. British journal of cancer, 2002, Jun-05, Volume: 86, Issue:11 Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filg	2002
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors. Advances in experimental medicine and biology, 1992, Volume: 324 Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances;	1992
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1991, Volume: 32, Issue:10 Topics: Aged; Bone Neoplasms; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Organometallic Comp	1991
Hypercalcemia and bone metastases in breast cancer. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper	1990
Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. The Journal of urology, 1989, Volume: 141, Issue:1 Topics: Bone Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Humans; Ma	1989
Strontium-89 therapy for the pain of osseous metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1985, Volume: 26, Issue:4 Topics: Bone Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Etidronic Acid; Fem	1985

Article	Year
ESTIMATION OF HUMAN DOSE OF 188/186RE-HEDP COCKTAIL BASED ON OLINDA/EXM AND DISTRIBUTION DATA IN RATS. Radiation protection dosimetry, 2020, Aug-28, Volume: 190, Issue:2 Topics: Bone Neoplasms; Etidronic Acid; Humans; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distrib	2020
A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. The British journal of radiology, 2020, Nov-01, Volume: 93, Issue:1115 Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged;	2020
In Vitro Evaluation of Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:5 Topics: Bone Neoplasms; Cell Culture Techniques; Etidronic Acid; Female; Humans; Male; Organometallic Compou	2017
Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2017, Volume: 129 Topics: Animals; Bone and Bones; Bone Neoplasms; Drug Stability; Etidronic Acid; Humans; In Vitro Techniques	2017
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. The British journal of radiology, 2018, Volume: 91, Issue:1084 Topics: Bone Neoplasms; Clinical Trials, Phase II as Topic; Etidronic Acid; Humans; Male; Organometallic Com	2018
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial	2013
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases. International journal of pharmaceutics, 2014, Apr-25, Volume: 465, Issue:1-2 Topics: Animals; Bone Neoplasms; Etidronic Acid; Feasibility Studies; Humans; Male; Mice; Organometallic Com	2014
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Molecular cancer, 2014, Dec-11, Volume: 13 Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line,	2014
Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data. Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:4 Topics: Bone Marrow; Bone Neoplasms; Etidronic Acid; Femur; Humans; Organophosphorus Compounds; Radiation Do	2015
A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation. Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:4 Topics: Bone Neoplasms; Etidronic Acid; Freeze Drying; Humans; Organometallic Compounds; Pain; Palliative Ca	2016
Phase I/II trials of European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:4 Topics: Bone Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Etidronic Aci	2017
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines. Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant;	2017
A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues. Journal of inorganic biochemistry, 2008, Volume: 102, Issue:12 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Crystalli	2008
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochemical and biophysical research communications, 2008, Dec-12, Volume: 377, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model	2008
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer research, 2008, Nov-01, Volume: 68, Issue:21 Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combinati	2008
Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP. Nuklearmedizin. Nuclear medicine, 2009, Volume: 48, Issue:1 Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male;	2009
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. International journal of cancer, 2009, Sep-01, Volume: 125, Issue:5 Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone	2009
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nuclear medicine communications, 2009, Volume: 30, Issue:9 Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal;	2009
Risedronate inhibits human osteosarcoma cell invasion. Journal of experimental & clinical cancer research : CR, 2009, Jul-22, Volume: 28 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Prol	2009
Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials, 2009, Volume: 30, Issue:31 Topics: Animals; Antinematodal Agents; beta-Cyclodextrins; Bone Neoplasms; Drug Delivery Systems; Etidronic	2009
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidro	2009
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser	2010
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell L	2010
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. Revue de stomatologie et de chirurgie maxillo-faciale, 2010, Volume: 111, Issue:4 Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu	2010
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ka	2011
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:11 Topics: Aged; Bone Neoplasms; Drug Resistance, Neoplasm; Etidronic Acid; Follow-Up Studies; Hormones; Humans	2011
Orthopaedics: Structural support. Nature, 2011, Dec-14, Volume: 480, Issue:7377 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosph	2011
Potential genotoxic effect of 186Re-HEDP on human lymphocyte cells: in-vitro evaluation with micronucleus-FISH analysis. Nuclear medicine communications, 2012, Volume: 33, Issue:4 Topics: Adult; Bone Neoplasms; Etidronic Acid; Female; Humans; In Situ Hybridization, Fluorescence; Lymphocy	2012
Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:8 Topics: Bone Neoplasms; Drug Resistance, Neoplasm; Etidronic Acid; Hormones; Humans; Male; Organometallic Co	2012
Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. The American journal of hospice & palliative care, 2013, Volume: 30, Issue:8 Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Pain; Palliative Care; Prostatic N	2013
Transient relief of metastatic cancer bone pain by oral administration of etidronate. Journal of bone and mineral metabolism, 2002, Volume: 20, Issue:4 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analgesics, Non-Narcotic; Biomarkers; Bone and Bon	2002
EANM procedure guidelines for treatment of refractory metastatic bone pain. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:3 Topics: Bone Neoplasms; Etidronic Acid; Europe; Humans; Nuclear Medicine; Organometallic Compounds; Organoph	2003
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:5 Topics: Adult; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Follow-U	2003
The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer. Cancer biotherapy & radiopharmaceuticals, 2005, Volume: 20, Issue:2 Topics: Bone and Bones; Bone Neoplasms; Etidronic Acid; Humans; Image Processing, Computer-Assisted; Male; N	2005
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urologia internationalis, 2006, Volume: 77, Issue:1 Topics: Aged; Bone Neoplasms; Etidronic Acid; Hemoglobins; Humans; Male; Organometallic Compounds; Pain; Pre	2006
Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:7 Topics: Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Models, Biological; Monte Carlo Method;	2007
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. British dental journal, 2007, Jul-28, Volume: 203, Issue:2 Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo	2007
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:7 Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphospho	2008
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases. European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:7 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Dipho	2008
Re-186 HEDP treatment in breast cancer patients with bone metastases. Journal of the National Medical Association, 2008, Volume: 100, Issue:4 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Dipho	2008
Etidronate for relief of metastatic bone pain. The Medical journal of Australia, 1983, Jul-09, Volume: 2, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Palliative Care	1983
Diphosphonate bone scanning agents--current concepts. European journal of nuclear medicine, 1982, Volume: 7, Issue:11 Topics: Bone Diseases; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Organotechnetium Compounds; R	1982
[Diphosphonates in the treatment of hypercalcemia]. La Revue de medecine interne, 1984, Volume: 5, Issue:4 Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyr	1984
[Clinical studies on the detection of bone metastasis in lung cancer by bone scintigraphy]. Kaku igaku. The Japanese journal of nuclear medicine, 1983, Volume: 20, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Bone and Bones; Bone Neoplasms; Carcinoma, Small Cell; Carcinoma, Squam	1983
[Pseudosarcomatous osteolysis in a Paget's disease patient treated with disodium etidronate (EHDP)]. Revue du rhumatisme et des maladies osteo-articulaires, 1984, Volume: 51, Issue:1 Topics: Bone Neoplasms; Bone Resorption; Calcitonin; Diagnosis, Differential; Etidronic Acid; Humans; Male;	1984
[Evaluation of bone diseases using dynamic bone scintigraphy]. Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 1983, Dec-25, Volume: 43, Issue:12 Topics: Adolescent; Adult; Bone and Bones; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Etidronic	1983
Effects of disodium etidronate in murine tumor models. European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:5 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Etidronic Acid; Hypercalcemia	1984
186Re-HEDP: a potential therapeutic bone agent. Nuklearmedizin. Nuclear medicine, 1984, Volume: 23, Issue:2 Topics: Animals; Bone and Bones; Bone Neoplasms; Dogs; Etidronic Acid; Mice; Radioisotopes; Radionuclide Ima	1984
Scintigraphic evaluation of primary bone tumors. Comparison of technetium-99m phosphonate and gallium citrate imaging. The Journal of bone and joint surgery. American volume, 1980, Volume: 62, Issue:5 Topics: Bone Neoplasms; Chondrosarcoma; Diphosphonates; Etidronic Acid; Gallium Radioisotopes; Humans; Organ	1980
Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. Acta medica Scandinavica, 1980, Volume: 208, Issue:4 Topics: Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Multiple Myeloma; Organotechnetium Compounds	1980
Parenteral diphosphonates for treating malignant hypercalcemia. Cancer, 1981, Oct-15, Volume: 48, Issue:8 Topics: Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration	1981
[Giant cell tumor of the bone (author's transl)]. Rinsho hoshasen. Clinical radiography, 1981, Aug-26, Volume: 26, Issue:8 Topics: Adult; Bone Neoplasms; Diphosphonates; Etidronic Acid; Female; Gallium Radioisotopes; Giant Cell Tum	1981
A radiopharmaceutical and clinical comparison of 99mTc-Sn-hydroxymethylene diphosphonate with 99mTc-Sn-hydroxyethylidene diphosphonate. Radiology, 1980, Volume: 136, Issue:3 Topics: Adult; Aged; Bone Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Orga	1980
[Thyroid cancer with a ring-shaped accumulation of 99mTc-EHDP: a case report (author's transl)]. Kaku igaku. The Japanese journal of nuclear medicine, 1980, Volume: 17, Issue:5 Topics: Adult; Bone and Bones; Bone Neoplasms; Etidronic Acid; Female; Humans; Organotechnetium Compounds; R	1980
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer research, 1995, Aug-15, Volume: 55, Issue:16 Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid	1995
Pain palliation and nuclear medicine. European journal of nuclear medicine, 1993, Volume: 20, Issue:1 Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Organophosphorus Compounds; Pain,	1993
A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1995, Volume: 36, Issue:2 Topics: Algorithms; Autoradiography; Bone Neoplasms; Etidronic Acid; Humans; Monte Carlo Method; Organometal	1995
Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Huma	1994
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:2 Topics: Adenocarcinoma; Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Neoplasms; Bone Res	1994
Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:1 Topics: Aged; Bone Marrow; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Ma	1996
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:10 Topics: Animals; Apoptosis; Bone Neoplasms; Cell Survival; Cells, Cultured; Diphosphonates; Etidronic Acid;	1995
[Biphosphonates]. Revue medicale de Liege, 1996, Volume: 51, Issue:1 Topics: Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Diphosphonates; Etidronic Acid; Humans; O	1996
Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:3 Topics: Bone Neoplasms; Cranial Nerve Diseases; Etidronic Acid; Glossopharyngeal Nerve; Humans; Hypoglossal	1996
Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. The Clinical journal of pain, 1995, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Female; Hospice Care; Humans; Male; Middle	1995
Etidronate and calcitonin for cancer bone pain. American family physician, 1996, Sep-15, Volume: 54, Issue:4 Topics: Analgesics; Bone Neoplasms; Calcitonin; Drug Administration Schedule; Etidronic Acid; Humans; Pain	1996
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. The Canadian journal of oncology, 1995, Volume: 5 Suppl 1 Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D	1995
Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. European journal of nuclear medicine, 1997, Volume: 24, Issue:6 Topics: Animals; Bone Neoplasms; Etidronic Acid; Half-Life; Humans; Male; Rabbits; Radiation Dosage; Radiois	1997
Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 1997, Volume: 48, Issue:3 Topics: Administration, Oral; Aged; Bone and Bones; Bone Diseases; Bone Neoplasms; Contraindications; Drug I	1997
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study. Nuclear medicine communications, 1997, Volume: 18, Issue:6 Topics: Adult; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ki	1997
[Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)]. Der Urologe. Ausg. A, 1997, Volume: 36, Issue:6 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Middle Aged;	1997
[Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP]. Zentralblatt fur Gynakologie, 1998, Volume: 120, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Middle Aged; Pain Measurement; Pal	1998
Rhenium-188(Sn)HEDP for treatment of osseous metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:4 Topics: Aged; Animals; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds;	1998
[Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:7 Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Pain Measurement; Palliative Care; Prostatic Neoplasms	1998
Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP. Clinical nuclear medicine, 1998, Volume: 23, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal,	1998
Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clinical nuclear medicine, 1999, Volume: 24, Issue:9 Topics: Adult; Aged; Analgesics; Blood Cell Count; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female;	1999
Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clinical nuclear medicine, 1999, Volume: 24, Issue:11 Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radionuclide	1999
Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. Nuclear medicine and biology, 1999, Volume: 26, Issue:8 Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Etidronic Acid; Injections, Intravenous; Is	1999
Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:4 Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Org	2000
Advances in our understanding of the treatment of painful bone metastasis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:4 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa	2000
Quantifying leukocyte and thrombocyte suppression-recovery after Re-186 HEDP for bone metastases. Clinical nuclear medicine, 2000, Volume: 25, Issue:6 Topics: Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Etidronic Acid; Female; F	2000
[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP]. MMW Fortschritte der Medizin, 1999, Nov-04, Volume: 141, Issue:44 Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prost	1999
Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer biotherapy & radiopharmaceuticals, 2000, Volume: 15, Issue:3 Topics: Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; P	2000
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Annals of nuclear medicine, 2000, Volume: 14, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lu	2000
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. Clinical nuclear medicine, 2000, Volume: 25, Issue:11 Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Palliativ	2000
Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:2 Topics: Aged; Bone and Bones; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Muscle, Ske	2001
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. European journal of nuclear medicine, 2001, Volume: 28, Issue:7 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Humans; Injections, Intravenous; Male; Midd	2001
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Nuclear medicine and biology, 2001, Volume: 28, Issue:6 Topics: Analgesics; Animals; Bone Neoplasms; Etidronic Acid; Heterocyclic Compounds, 1-Ring; Injections, Int	2001
Rhenium-188 HEDP to treat painful bone metastases. Clinical nuclear medicine, 2001, Volume: 26, Issue:11 Topics: Bone Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Age	2001
[Clinical evaluation of bone scintigraphy with 99mTc-labeled phosphate compounds. I. Metastatic bone tumor (author's transl]. Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 1978, Sep-25, Volume: 38, Issue:9 Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Etidronic Acid; Evaluation Studies as Topic; Female; Hu	1978
A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.P. European journal of nuclear medicine, 1978, Volume: 3, Issue:1 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Ne	1978
Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. The International journal of applied radiation and isotopes, 1979, Volume: 30, Issue:12 Topics: Animals; Bone Neoplasms; Etidronic Acid; Isotope Labeling; Radioisotopes; Radionuclide Imaging; Rats	1979
Technetium-99m-labeled methylene diphosphonate and hydroxyethylidine diphosphonate--biologic and clinical comparison: concise communication. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1979, Volume: 20, Issue:8 Topics: Adult; Aged; Bone Diseases; Bone Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Mi	1979
A clinical comparison of Tc-99m HEDP and Tc-99m MDP. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1979, Volume: 20, Issue:8 Topics: Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Radionuclide Imaging; Statistics as Topic; T	1979
[Comparative investigations concerning osteotropic radiopharmaceuticals. III. Scanning with 18F and 99mTc-malignant diseases (author's transl)]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1975, Volume: 123, Issue:5 Topics: Abscess; Bone Diseases; Bone Neoplasms; Etidronic Acid; Female; Fluorine; Humans; Inflammation; Join	1975
The use of 99mc-EHDP as a scanning agent in the detection of metastases from osteosarcoma. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1977, Volume: 126, Issue:6 Topics: Adolescent; Adult; Aged; Amputation Stumps; Bone Neoplasms; Child; Epiphyses; Etidronic Acid; Female	1977
Comparison of 99mTc-labelled polyphosphate, pyrophosphate and ethane hydroxy diphosphonate in patients with skeletal metastases and in normal subjects. Strahlentherapie. Sonderbande, 1975, Volume: 74 Topics: Bone Neoplasms; Diphosphates; Etidronic Acid; Humans; Neoplasm Metastasis; Organophosphorus Compound	1975
Clinical comparison of technetium-99m diphosphonate and pyrophosphate in bone scintigraphy: concise communication. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1978, Volume: 19, Issue:2 Topics: Bone Neoplasms; Diphosphates; Etidronic Acid; Evaluation Studies as Topic; Humans; Neoplasm Metastas	1978
An evaluation of the in vivo properties of 99mTc-HEDP. Radiology, 1977, Volume: 122, Issue:1 Topics: Bone Neoplasms; Drug Storage; Etidronic Acid; Evaluation Studies as Topic; Humans; Radionuclide Imag	1977
Clinical evaluation of some phosphorus bone-imaging agents: concise communication. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1977, Volume: 18, Issue:6 Topics: Analysis of Variance; Bone Diseases; Bone Neoplasms; Etidronic Acid; Evaluation Studies as Topic; Hu	1977
[Bone scanning by whole body camera of metastatic bone tumors with Tc-99m EDHP]. Kaku igaku. The Japanese journal of nuclear medicine, 1977, Volume: 14, Issue:2 Topics: Aged; Bone and Bones; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Neoplasm Me	1977
Bone scintigraphy as a guide to the diagnosis of osteoid osteoma. Radiologia clinica, 1977, Volume: 46, Issue:4 Topics: Adolescent; Bone Neoplasms; Child; Etidronic Acid; Female; Femoral Neoplasms; Humans; Lumbar Vertebr	1977
Bone scan appearance of a Paget's osteosarcoma: failure to concentrate HEDP. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1977, Volume: 18, Issue:10 Topics: Bone Neoplasms; Etidronic Acid; Female; Humans; Middle Aged; Osteitis Deformans; Osteosarcoma; Radio	1977
[Clinical evaluation of bone scintigraphy using a commercial 99mTc-EHDP preparation]. Kaku igaku. The Japanese journal of nuclear medicine, 1977, Volume: 14, Issue:4 Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Child, Preschool; Etidronic Acid; Female; Humans; Ma	1977
[32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1978, Volume: 19, Issue:1 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis	1978
Bone scanning: the current position. Scottish medical journal, 1975, Volume: 20, Issue:4 Topics: Bone Neoplasms; Etidronic Acid; Humans; Neoplasm Metastasis; Radionuclide Imaging; Technetium	1975
Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1975, Volume: 16, Issue:10 Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung	1975
Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1975, Volume: 16, Issue:11 Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Neoplasm Met	1975
Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clinical nuclear medicine, 1992, Volume: 17, Issue:1 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain,	1992
Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:5 Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Half-Life; Humans; Male; Middle Aged	1992
Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:5 Topics: Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Drug Interactions;	1992
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology, 1990, Volume: 176, Issue:1 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Estrogens; Etidronic Acid; Humans; Male; Organometallic Compou	1990
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:8 Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp	1991
[Current possibilities in the therapy and prevention of bone metastases in breast carcinoma?]. Zentralblatt fur Gynakologie, 1991, Volume: 113, Issue:19 Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Etidronic Acid; Female; Humans	1991
Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. The Prostate, 1991, Volume: 19, Issue:2 Topics: Animals; Bone Neoplasms; Calcium; Cell Line; Disease Models, Animal; Etidronic Acid; Injections, Sub	1991
Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology, 1988, Volume: 32, Issue:5 Topics: Administration, Oral; Bone Neoplasms; Etidronic Acid; Humans; Male; Orchiectomy; Pain Measurement; P	1988
Prevention of ectopic bone formation by local application of ethane-1-hydroxy-1,1-diphosphonate (EHDP): an experimental study in rabbits. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 1986, Volume: 4, Issue:1 Topics: Animals; Bone and Bones; Bone Cements; Bone Neoplasms; Choristoma; Dose-Response Relationship, Drug;	1986
Diagnosis and management of Paget's disease. Comprehensive therapy, 1986, Volume: 12, Issue:3 Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Calcitonin; Etidronic Acid; Fractures, Bone; Humans; Mi	1986
The role of bone scintigraphy in osteogenic sarcoma. Skeletal radiology, 1986, Volume: 15, Issue:5 Topics: Adolescent; Bone Neoplasms; Child; Child, Preschool; Etidronic Acid; Female; Humans; Lung Neoplasms;	1986
Influence of complex charge and size on the uptake of 99mTc-diphosphonates in osteogenic tissue. International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, 1986, Volume: 13, Issue:1 Topics: Animals; Bone and Bones; Bone Neoplasms; Carcinoma 256, Walker; Etidronic Acid; Gastric Mucosa; Male	1986
The value of non-staging skeletal scintigraphy in breast cancer. Clinical radiology, 1986, Volume: 37, Issue:6 Topics: Actuarial Analysis; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Follow-Up Stud	1986
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:1 Topics: Aged; Biopsy; Bone Neoplasms; Bone Resorption; Calcitonin; Carcinoma; Etidronic Acid; Humans; Ilium;	1987
Relief of metastatic bone pain with etidronate disodium. Ohio medicine : journal of the Ohio State Medical Association, 1987, Volume: 83, Issue:1 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Pain	1987
Rationale for diphosphonate therapy in hypercalcemia of malignancy. Introduction. The American journal of medicine, 1987, Feb-23, Volume: 82, Issue:2A Topics: Bone Neoplasms; Etidronic Acid; Humans; Hypercalcemia; Kidney; Osteoclasts; Paraneoplastic Endocrine	1987
Effect of etidronate disodium on the interactions between malignancy and bone. The American journal of medicine, 1987, Feb-23, Volume: 82, Issue:2A Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Etidronic Acid; Hypercalcemia; Mice; Osteolysis; Par	1987
153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, 1987, Volume: 14, Issue:3 Topics: Animals; Bone Neoplasms; Dogs; Etidronic Acid; Humans; Kinetics; Organophosphorus Compounds; Pain; R	1987
A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium. Journal of cancer research and clinical oncology, 1987, Volume: 113, Issue:6 Topics: Animals; Bone Neoplasms; Bone Resorption; Etidronic Acid; Mice; Neoplasm Transplantation; Neoplasms,	1987
Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology, 1988, Volume: 166, Issue:2 Topics: Adult; Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Radioisotopes; Radio	1988
False-negative bone imaging due to etidronate disodium therapy. Clinical nuclear medicine, 1988, Volume: 13, Issue:4 Topics: Aged; Bone Neoplasms; Etidronic Acid; False Negative Reactions; Humans; Male; Prostatic Neoplasms; R	1988
[Effects of etidronate disodium (EHDP) on urogenital malignancies with bone metastasis: a multicentered collaborative evaluation]. Hinyokika kiyo. Acta urologica Japonica, 1988, Volume: 34, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Drug Evaluat	1988
Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice. The Journal of urology, 1988, Volume: 140, Issue:4 Topics: Adenocarcinoma; Animals; Bone Neoplasms; Cell Line; Etidronic Acid; Male; Mice; Neoplasm Invasivenes	1988
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis. Nephron, 1985, Volume: 39, Issue:4 Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid;	1985
An experimental rat model of local bone cancer invasion and its responsiveness to ethane-1-hydroxy-1,1-bis(phosphonate). Cancer research, 1985, Volume: 45, Issue:5 Topics: Animals; Bone and Bones; Bone Neoplasms; Calcium; Carcinoma 256, Walker; Disease Models, Animal; Eti	1985
Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity. Radiology, 1973, Volume: 107, Issue:3 Topics: Bone Neoplasms; Etidronic Acid; Fluorine; Humans; Organophosphorus Compounds; Radiography; Radioisot	1973

etidronate and Bone Cancer

Research Excerpts

Research

Studies (203)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Overall Survival

Progression-free Survival

Time to First Skeletal Related Event

Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol

Hypercalcemia

Percent Change of Serum CTX From Baseline to Week 25

Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25

Skeletal Related Events

Time to First Skeletal Related Event

Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25

Time to the First On-Study SRE (Non-inferiority)

Time to the First On-Study SRE (Superiority)

Time to the First-And-Subsequent On-Study SRE

Numbers of SRE or Death Occurred Cumulatively

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

Three- Year Survival Rate

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

Bone Turnover Marker Changes-- Serum BAP

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

Reviews

Trials

Other Studies